drugset
drugset / Trial / NCT03362606

Engineered Immune Effectors Against Ovarian Cancer

NCT03362606 ↗

Phase 1/2 Recruiting 20 enrolled Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.

Timeline

Start
2026-06-01
Primary completion
2029-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject OC-CTLs Cell therapy 100000 cells/kg Intravenous
Subject OC-CTLs Cell therapy 4e+06 cells/kg Intravenous

Indications

ovarian cancer